Item 1.01. Entry into a Material Definitive Agreement.
Viveve Medical, Inc. (the "Company"), previously entered into a purchase
agreement on June 8, 2020 (the "Purchase Agreement") with Lincoln Park Capital
Fund, LLC ("LPC"), which provided that the Company had the right, in its sole
discretion, to sell to LPC up to $10 million of shares of the Company's common
stock, par value $0.0001 per share ("Common Stock") from time to time over a
30-month period pursuant to the terms of the Purchase Agreement. The Purchase
Agreement limited the Company's sale shares of Common Stock to LPC to 3,017,625
shares of Common Stock (or 301,762 shares after giving effect to the Company's
reverse stock split in December 2020), representing 19.99% of the shares of the
Common Stock outstanding on the date of the Purchase Agreement unless (i)
shareholder approval was obtained to issue more than such amount or (ii) the
average price of all applicable sales of Common Stock to Lincoln Park under the
Purchase Agreement equaled or exceeded $0.646 per share (or $6.46 per share
after giving effect to the Company's reverse stock split), which represented the
lower of (A) the closing price of the Common Stock on the Nasdaq Capital Market
immediately preceding the date of the Purchase Agreement or (B) the average of
the closing price of the Common Stock on the Nasdaq Capital Market for the five
business days immediately preceding the date of the Purchase Agreement, as
calculated in accordance with Nasdaq Rules.
On March 31, 2021, the Company and LPC entered into a First Amendment to
Purchase Agreement (the "Amendment"). The Amendment limited the Company's sale
shares of Common Stock to LPC from the date thereof to 2,068,342 shares of
shares of Common Stock, representing 19.99% of the shares of the Common Stock
outstanding on the date of Amendment unless (i) shareholder approval is obtained
to issue more than such amount or (ii) the average price of all applicable sales
of Common Stock to Lincoln Park under the Purchase Agreement, as amended equals
or exceeds $2.99 per share, which represents the lower of (A) the closing price
of the Common Stock on the Nasdaq Capital Market immediately preceding the date
of the Amendment or (B) the average of the closing prices of the Common Stock on
the Nasdaq Capital Market for the five business days immediately preceding the
date of the Amendment, as calculated in accordance with Nasdaq Rules.
The foregoing description of the Amendment is qualified in its entirety by
reference to the full text of the Amendment, a copy which is attached hereto as
Exhibit 10.1, and which is incorporated herein in its entirety by reference.
--------------------------------------------------------------------------------
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
10.1 First Amendment to Purchase
Agreement, dated March 31, 2021, by
and between Viveve Medical, Inc. and
Lincoln Park Capital Fund, LLC.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses